Smith & Nephew released largely in line Q4/FY 22 numbers but slashed its mid-term margin outlook to reflect the macro-economic uncertainty.
Q4/FY growth was attributable to a broad-based recovery in Orthopaedics supporting the ex-orthopaedics momentum.
The performance was overshadowed by the encouraging growth outlook – for FY23 as well as for the mid-term – which was cheered by investors, who ignored the softer than expected margin outlook, sending the stock 4.2% higher in trade.
22 Feb 2023
Q4 22: encouraging growth outlook makes up for slower margin trajectory
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q4 22: encouraging growth outlook makes up for slower margin trajectory
Smith & Nephew plc (SN:LON) | 973 120.7 1.3% | Mkt Cap: 8,507m
- Published:
22 Feb 2023 -
Author:
Virendra Chauhan -
Pages:
4
Smith & Nephew released largely in line Q4/FY 22 numbers but slashed its mid-term margin outlook to reflect the macro-economic uncertainty.
Q4/FY growth was attributable to a broad-based recovery in Orthopaedics supporting the ex-orthopaedics momentum.
The performance was overshadowed by the encouraging growth outlook – for FY23 as well as for the mid-term – which was cheered by investors, who ignored the softer than expected margin outlook, sending the stock 4.2% higher in trade.